Citation

Lotrich F. Curr. Hepat. Rep. 2010; 9(2): 113-118.

Copyright

(Copyright © 2010)

DOI

10.1007/s11901-010-0035-5

PMID

unavailable

Abstract

Depression and other influences on mental health can impact antiviral response rates during chronic hepatitis C treatment, the quality of life for these patients, and the risk for adverse outcomes such as suicide. Enhanced treatment outcomes for patients who are receiving interferon-α requires 1) addressing preexisting mental health problems, 2) alleviating psychiatric conditions that emerge during treatment, and 3) prediction and prevention of these conditions. Accumulating evidence indicates that these three goals are feasible. Collaborative involvement of psychiatric management may often be critical in this regard. © 2010 Springer Science+Business Media, LLC.

Language: en

Keywords

Prevention; human; Depression; Treatment; insomnia; depression; anger; psychosis; major depression; Screening; clinical trial; treatment outcome; comorbidity; prediction; review; fatigue; mental disease; citalopram; mirtazapine; serotonin uptake inhibitor; patient monitoring; anxiety disorder; sleep disorder; placebo; benzodiazepine derivative; trazodone; drug efficacy; drug tolerability; alpha interferon; Interferon; hepatitis C; irritability; mania; side effect; methylphenidate; pruritus; liver toxicity; modafinil; dizziness; kinesiotherapy; patient assessment; integrated health care system; daytime somnolence; hydroxyzine